Venus Medtech (Hangzhou) logo

Venus Medtech (Hangzhou)(SEHK) 2500

Market CapHK$461.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-98%
5 Year-97%
1 Year-62%
1 Month-1%
HK$1.09
+2.84%
+0.03Today
Venus Medtech (Hangzhou) last closing stock price
MetricPriceDate
Last closeHKD 1.092026-10-15
Venus Medtech (Hangzhou) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.39%HKD 1.142026-10-08
1 month-0.91%HKD 1.102026-09-15
3 month-12.8%HKD 1.252026-07-17
Year to date-54.2%HKD 2.382025-12-31
1 year-62.02%HKD 2.872025-10-15
3 year-75.45%HKD 4.442023-10-16
5 year-97.39%HKD 41.702021-10-15
Since inception-97.55%HKD 43.052019-12-10

Venus Medtech (Hangzhou) Financials at a Glance

Market Cap

HK$461.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥682.55M

Net Income (TTM)

-CN¥1.11B

EPS (TTM)

-HK$1.18

P/E Ratio

-0.89

Dividend

HK$0.00

Beta (Volatility)

-0.34 (Low)

Price

HK$1.09

Volume

668,450

Open

HK$1.03

Previous Close

HK$1.06

Daily Range

HK$0.99 - HK$1.09

52-Week Range

HK$0.94 - HK$3.86

Estimated Earnings Date

Apr 1, 2027

2500 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Venus Medtech (Hangzhou)

Venus Medtech (Hangzhou) Inc. is a leading innovator in the medical device industry, specializing in the research, development, manufacturing, and sale of bioprosthetic heart valves. The company offers a range of transcatheter heart valve replacement products and other advanced medical technologies aimed at improving patient outcomes in cardiovascular care.

Products and Services
  • Transcatheter aortic heart valve replacement products, including VenusA-Valve and VenusP-Valve
  • Innovative devices like Cardiovalve for mitral regurgitation treatment
  • Procedural accessories such as catheter sheath products and balloon catheters
Growth Outlook
  • Significant market potential in China's cardiovascular device sector
  • Ongoing clinical trials for new products, enhancing future revenue streams
  • Strategic partnerships aimed at expanding international market reach
Financial Highlights
  • Recent quarterly revenue of 135.65 million CNY, showing growth potential
  • Trailing twelve months (TTM) gross profit margin at 53.1%, indicating operational efficiency
  • Current ratio of 1.30, reflecting solid short-term financial health
Venus Medtech (Hangzhou) Inc. has established itself as a key player in the medical device industry, particularly in the field of cardiovascular solutions. The company's diverse product offerings, including advanced heart valve technologies, position it well to capitalize on the growing demand for innovative medical devices. The growth outlook remains promising, supported by ongoing clinical trials and strategic partnerships that aim to enhance market presence both domestically and internationally. Financially, the company has demonstrated resilience, with a recent quarterly revenue of 135.65 million CNY, reflecting a positive trajectory. The gross profit margin of 53.1% indicates effective cost management and operational efficiency, while a current ratio of 1.30 suggests a strong ability to meet short-term obligations. These financial metrics highlight the potential for future growth and stability, making Venus Medtech an intriguing option for investors interested in the healthcare sector.
AI Generated • Oct 13, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

560

CEO

Hou-Sen Lim

Website

www.venusmedtech.com

Headquarters

Hangzhou, ZH 310051, CN

2500 Financials

Key Financial Metrics (TTM)

Gross Margin

53.10%

Operating Margin

-148.84%

Net Income Margin

-181.92%

Return on Equity

-28.24%

Return on Capital

-17.44%

Return on Assets

-20.89%

Earnings Yield

-1.12%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$461.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

437.90M

Volume

668.45K

Avg. Volume

704.38K

Financials (TTM)

Gross Profit

CN¥459.55M

Operating Income

-CN¥657.79M

EBITDA

-CN¥816.66M

Operating Cash Flow

-CN¥570.23M

Capital Expenditure

-CN¥13.06M

Free Cash Flow

-CN¥583.29M

Cash & ST Invst.

CN¥88.20M

Total Debt

CN¥202.65M

Venus Medtech (Hangzhou) Performance Analysis

Venus Medtech (Hangzhou) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 472,664,635-5.7%
20232023-12-31CNY 542,966,18114.9%
20242024-12-31CNY 510,488,364-6.0%
20252025-12-31CNY 332,716,587-34.8%
Venus Medtech (Hangzhou) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-314.1%
Q22025-06-30-22.1%
Q42025-12-31-36.1%
Q22026-06-3013.4%
Venus Medtech (Hangzhou) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -2.81173.5%
20232023-12-31CNY -1.78-36.8%
20242024-12-31CNY -1.77-0.4%
20252025-12-31CNY -1.01-42.9%
Venus Medtech (Hangzhou) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-146.8%
Q22025-06-3073.3%
Q42025-12-31-100.0%
Q22026-06-3029.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥135.65M

-41.2%

Gross Profit

CN¥61.73M

-66.0%

Gross Margin

45.51%

N/A

Market Cap

HK$461.98MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$829.41K

N/A

Employees

557

N/A

Net Income

-CN¥191.52M

+7.2%

EBITDA

-CN¥139.89M

+20.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥88.20M

-81.8%

Total Debt

CN¥202.65M

-59.3%

Accounts Receivable

CN¥204.76M

-25.0%

Inventory

CN¥93.01M

-24.8%

Long Term Debt

CN¥7.42M

-97.8%

Short Term Debt

CN¥195.23M

+18.6%

Return on Assets

-20.89%

N/A

Return on Invested Capital

-20.33%

N/A

Free Cash Flow

-CN¥167.31M

-532.4%

Operating Cash Flow

-CN¥163.86M

-299.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,721.68+0.00%
^DJIDJI
$52,076.17+0.01%
^IXICNASDAQ
$26,579.10-0.00%
BTCBitcoin
$82,037.00+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.61-0.39%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$102.92-6.89%
CRWVCoreWeave
$68.32+3.86%
INTCIntel
$94.19-4.00%

Questions About 2500

What is the current price of Venus Medtech (Hangzhou)?

Venus Medtech (Hangzhou) is trading at HK$1.09 per share.

What is the 52-week range for Venus Medtech (Hangzhou)?

Over the past 52 weeks, Venus Medtech (Hangzhou) has traded between HK$0.94 and HK$3.86.

How much debt does Venus Medtech (Hangzhou) have?

As of the most recent reporting period, Venus Medtech (Hangzhou) reported total debt of CN¥240.96M.

How much cash does Venus Medtech (Hangzhou) have on hand?

Venus Medtech (Hangzhou) reported CN¥194.88M in cash and cash equivalents in its most recent financial results.

What is Venus Medtech (Hangzhou)’s dividend yield?

Venus Medtech (Hangzhou) does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services